Programme Overview

Advancing plasma therapeutics from early research to clinical trials

(Sami Chtourou, K2C-BIOPHARM)

Safety, Quality and Regulatory aspects of plasma fractionation

(Beatrice Biebuyck, Takeda)

Novel technologies and solutions for plasma fractionation

(Merche Faro, Grifols)

Plasma 4.0 – digital transformation of the plasma business and manufacturing

(Barbara Kalina, CSL Behring)

Future perspectives on the plasma business and market 

(Eric Youssef, Cytiva)

Next Generation Sequencing: Applications of this powerful tool for adventitious virus testing in biological products

Andy Bailey, ViruSure

Panel discussion with

Dr. Thomas Kriel, Head of Pathogen Safety at Takeda

Dr. Dorothy Scott, Branch Chief, Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, FDA

Dominika Misztela, Sr. Director, Regulatory Policy Europe at PPTA

Saleh Yusuf, MBA, LSSBB, Director of North America Logistics, Kedrion Biopharma Inc

Next Generation Bioprocessing Using Novel Materials and Ligand Chemistries

Lynne Deakin 3M Company

Yield optimization of plasma fraction purification using mechanistic chromatography modeling

Paul Sylvain, Takeda

The impact of Covid-19 and other events on the plasma fractionation industry - Historical Perspective and Lessons Learned (or Not)

Patrick Robert, MRB

Plasma fractionation and downstream processing of human polyclonal antibodies from the DiversitAb™ platform

Christoph Bausch, SAb Biotherapeutics

Virus inactivation by UV-C irradiation of plasma proteins

Gerhard Poelsler, Biotest

Technology Transfer during the COVID pandemic: Leveraging Communication Platforms and Mixed Reality

Pushpa Kotharu, CSL Behring

Multiple challenges impact future perspectives

Jan Bult, JMB Consultancy BV

Efficacy and safety of SAB-185, a novel SARS-Cov-2 Immunotherapeutic: a phase 1/1b..

Christoph Bausch, SAb Biotherapeutics

Novel Dual Affinity Protein technology provide 80% increase in yield of IVIG

Jan Kyhse-Andersen, CHRETO

Overcoming manufacturing challenges for the super orphan plasma-derived drug BabyBIG® used to treat infant botulism

Patrick Gavit, Takeda

How plasma supply to meet the needs for plasma-derived medicines can bring value for public health systems

Leni Von Bonsdorff , IPFA

Next-Generation Fc Receptor–Targeting Biologics for Autoimmune Diseases

Fabian Käsermann, CSL Behring

Process Knowledge reboot: Applying QbD to legacy plasma products to modernize PPQ, Quality Management, and the regulatory dossier

Patrick Gregory, CSL Behring

Base Fractionation – Next Generation

Richard Weidemann CSL Behring

What can we expect from the plasma fractionation industry in the future?

John Curling, JCC AB